Leading the Way in Life Science Technologies

GEN Exclusives

More »

Insight & Intelligence™

Back to Item »

With Oligonucleotide Drugs, Antisense Arrives but RNAi Has a Long Way to Go

Isis filed an NDA for its HoFH antisense treatment, while Alnylam reported Phase III failure with RSV infection RNAi candidate.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »